https://www.selleckchem.com/pr....oducts/tefinostat.ht
Objectives To examine a relationship between protein C (PC) and antithrombin III (AT III) activities with ejection fraction of left ventricle (EFLV), in the early phase of acute ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI), and to investigate whether PC and AT III are associated with major adverse cardiovascular events (MACE) within 6 months following from pPCI. Patients and methods The research had a prospective character and included 357 patients who had, following the di
Like
Comment
Share
